The Clinical Application Of Ezetimibe In Membranous Nephropathy

Objective: In this experiment, by using clinical drugs respectively in two groups ofpatients (treatment group and control group), observing and comparing the clinicalefficacy, adverse reactions, and the difference between the change of the clinical testingindexes of the two different treatments, after giving the patients with membranousnephropathy combined dyslipidemia lipid adjusting treatment, to provide new ideas, newstrategies, better clinical lipid adjusting treatment and prevention of complications ofdyslipidemia for the patients with membranous nephropathy combined dyslipidemia inclinical lipid adjusting treatment.Methods: The research object was a total of60patients with kidney disease in ourhospital during January2012to December2013, the diagnosis consistent with primarynephrotic syndrome, at the same time, in line with the pathological diagnosis ofmembranous nephropathy, and the patients had not been received lipid adjustingtreatment4weeks before, their liver function and renal function were normal. Dividedthe patients into2groups, the experimental group (30cases), took simvastatin10mg,1time/day and the ezetimibe10mg,1time/day orally, the control group (30cases), tooksimvastatin20mg,1time/day orally. The rest of the membranous nephropathy specialisttreatments were the same. Detect the patients’ blood fat, serum transaminase, creatinekinase,24hours urinary protein level of quantitative indicators, then observed andrecorded each patients’ clinical drug adverse reactions before taking the medicine andafter two weeks, four weeks,8weeks after taking the medicine. Used SPSS16.0software package to process data, used the two independent samples t test to compare thetwo groups, the count data and the two sample rates were compared with chi-square test.With P <0.05for the difference was statistically significant. Result:①There was nostatistical difference in the lipid indexes level comparison of thepatients of the2groups after taking the medicines two weeks, four weeks, neither are thetransaminase, creatine kinase and24hours urinary protein quantitative level.(P>0.05)②T here was a statistical difference in the serum cholesterol levels between the2groups,and there was no statistical difference in the rest of the indicators after8weeks.(P>0.05)③After taking the medicines8weeks later, there was no statistical difference in theincidence of adverse reactions and lipid adjusting treatment effectiveness.(P>0.05)Conclusion:①In this experiment, compared with using simvastatin separately, usingsimvastatin and ezetimibe in patients with idiopathic membranous nephropathy clinicallipid adjusting treatment could reduce the absorption of cholesterol, further reduce thelevel of cholesterol in the blood plasma, better hit the Lipid target to avoid complicationscaused by dyslipidemia.②In this experiment, compared with control group, thecombination group had not increased the rate of the risk of abnormal liver function, andthere were no statistical difference in the incidence of adverse reactions of the digestivetract, etc, no serious adverse reactions such as muscle dissolved.